Ultresa and Vikoace: Two Newly Approved Pancreatic Enzyme Products

New Drugs , News / September 28, 2016
Ultresa is a delayed-release capsule used to treat children and adults with cystic fibrosis, a serious genetic disorder affecting the lungs and other organs; or other conditions which cannot digest food normally because the pancreas does not make enough pancreatic enzymes.

Viokace, in combination with a proton pump inhibitor, is used to treat adults who cannot digest food normally. Adults with chronic pancreatitis, a continuing, chronic inflammatory process of the pancreas; or those who have had some or all of their pancreas removed (pancreatectomy) may not digest food normally because they lack needed enzymes, or because their enzymes are not released into the intestines. Viokace’s safety and efficacy in children has not yet been established.

Ultresa and Viokace are the fourth and fifth pancreatic enzyme products approved by the FDA; others include Creon (2009), Zenpep (2009) and Pancreaze (2010).

Ultresa and Viokace are marketed by Bridgewater, N.J.-based Aptalis Pharma U.S. Inc.

No Comments

Leave a Reply

%d bloggers like this:
Skip to toolbar